Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.50 |
| ▸ | FABP7 | O15540 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 2/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL525363 | 0.94 | FABP5 (0.49) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL524690 | 0.93 | FABP5 (0.48) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL7401416 | 0.91 | FABP5 (0.47) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL4601669 | 0.88 | FABP5 (0.50) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL525667 | 0.88 | FABP5 (0.51) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL4601031 | 0.85 | FABP5 (0.45) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL4601703 | 0.84 | FABP5 (0.46) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL31631393 | 0.84 | FABP5 (0.46) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL4600771 | 0.83 | FABP5 (0.45) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL4602339 | 0.83 | FABP5 (0.45) | FABP5FABP7KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4208466-B1 | HIGH AFFINITY MACROCYCLIC FKB51-INHIBITORS FOR TREATMENT OF PSYCHIATRIC DISORDERS | UNIV DARMSTADT TECH (DE) | 2025-06-11 | — | — | EP | disclosed |
| WO-2025098422-A1 | MULTI-RECEPTOR CO-AGONIST COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 深圳信立泰药业股份有限公司 | 2025-05-15 | — | — | WO | disclosed |
| US-11834463-B2 | High affinity macrocyclic FKB51-inhibitors for treatment of psychiatric disorders | Technische Universität Darmstadt (DE) | 2023-12-05 | — | — | US | disclosed |
| EP-4208466-A1 | HIGH AFFINITY MACROCYCLIC FKB51-INHIBITORS FOR TREATMENT OF PSYCHIATRIC DISORDERS | Technische Universität Darmstadt (DE) | 2023-07-12 | — | — | EP | disclosed |
| US-20230212185-A1 | HIGH AFFINITY MACROCYCLIC FKB51-INHIBITORS FOR TREATMENT OF PSYCHIATRIC DISORDERS | Technische Universität Darmstadt (DE) | 2023-07-06 | — | — | US | disclosed |
| WO-2022049005-A1 | HIGH AFFINITY MACROCYCLIC FKB51-INHIBITORS FOR TREATMENT OF PSYCHIATRIC DISORDERS | Technische Universität Darmstadt (DE) | 2022-03-10 | — | — | WO | disclosed |
| EP-3964515-A1 | HIGH AFFINITY MACROCYCLIC FKB51-INHIBITORS FOR TREATMENT OF PSYCHIATRIC DISORDERS | Technische Universität Darmstadt (DE) | 2022-03-09 | — | — | EP | disclosed |
| CN-113788877-A | Novel insect kinin analogs and application thereof in aphid control | 中国农业大学 | 2021-12-14 | — | — | CN | disclosed |
| CN-109593061-B | Androgen receptor antagonist, preparation method and application thereof | 昆明积大制药股份有限公司 | 2021-09-14 | — | — | CN | disclosed |
| EP-3825324-A1 | CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | Merck Sharp & Dohme Corp. (US) | 2021-05-26 | — | — | EP | disclosed |
| CN-109438297-B | Androgen receptor antagonist, preparation method and application thereof | 昆明积大制药股份有限公司 | 2021-05-14 | — | — | CN | disclosed |
| EP-3209682-B1 | CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | MERCK SHARP & DOHME (US) | 2020-12-30 | — | — | EP | disclosed |
| US-10413593-B2 | Co-agonists of the glucagon and GLP-1 receptors | MERCK SHARP & DOHME CORP. (US) | 2019-09-17 | — | — | US | disclosed |
| CN-109438297-A | Androgen receptor antagonists, preparation method and its application | 昆明积大制药股份有限公司 | 2019-03-08 | — | — | CN | disclosed |
| US-20170360893-A1 | CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20160114000-A1 | CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | MERCK SHARP & DOHME CORP. | 2016-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360893-A1 | CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | GLP1R, GCGR, GCG | FABP5 385/4885FABP7 390/4885KMT2A 3311/4885 |
| US-20230212185-A1 | HIGH AFFINITY MACROCYCLIC FKB51-INHIBITORS FOR TREATMENT OF PSYCHIATRIC DISORDERS | FKBP1B, FKBP5, FKBP1A | FABP5 87/4885FABP7 20/4885KMT2A 1826/4885 |
| US-11834463-B2 | High affinity macrocyclic FKB51-inhibitors for treatment of psychiatric disorders | FKBP1B, FKBP5, FKBP1A | FABP5 87/4885FABP7 20/4885KMT2A 1826/4885 |
| US-20160114000-A1 | CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | GLP1R, GCGR, GCG | FABP5 414/4885FABP7 396/4885KMT2A 3275/4885 |
| US-10413593-B2 | Co-agonists of the glucagon and GLP-1 receptors | GLP1R, GCGR, GCG | FABP5 414/4885FABP7 396/4885KMT2A 3275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.